Cumulus Neuroscience has created a next-generation integrated physiological and digital biomarker platform.
Cumulus Neuroscience develops an AI-based digital biomarker platform to aid in the resolution of the most pressing healthcare challenges in neurodegeneration and psychiatry. Cumulus Neuroscience's platform is intended to provide the critical data and insight required for more rapid, robust, and cost-effective clinical trials that improve patient access to new therapies. The platform's novel insights change the future of clinical trials in brain disorders, allowing life-changing therapies to reach patients faster and more affordably.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
May 4, 2021 | Series Unknown | £6M | 3 | Dementia Discovery Fund | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Dementia Discovery Fund | Yes | Series Unknown |
UK Future Fund | — | Series Unknown |
LifeArc | — | Series Unknown |